VGXI, Inc., a leading provider of plasmid DNA manufacturing and development services, is proud to announce its participation in the upcoming Alliance for Regenerative Medicine Annual Meeting on the ...

BioIVT personnel to demonstrate its collaborative approach to designing and implementing in vitro ADME-Tox programs that set industry standards and achieve client goals The ACT (American College of ...

A novel study by researchers at the Icahn School of Medicine at Mount Sinai addresses a critical yet under-explored question in cancer research: Why is aging the biggest risk factor for cancer ...

This present study was designed to characterize the antitumor activity of saruparib in PDX models and compare efficacy in terms of preclinical complete response rate with the first-generation ...

Our objective is to make at least one new collaboration on one of our preclinical or clinical assets ... for SAN711 by year-end and finalize a GLP tox batch for SAN2355 during the third quarter." ...

Repare ended June with $208.1 million in cash and equivalents, which it had estimated would fund its operations until at least mid-2026. The savings outlined in the Aug. 28 release are expected to ...